Advantages and benefits of using the combination of mometasone furoate and olopatadine in the treatment of allergic rhinitis Review article
Main Article Content
Abstract
Allergic rhinitis (AR) is one of the most common chronic diseases worldwide. Management of AR is based on a strategy that includes allergen avoidance, pharmacotherapy, and allergen immunotherapy. Intranasal glucocorticosteroids (nGCS) and oral or intranasal antihistamines (LH1) are key components of treatment. However, despite their effectiveness, many patients still experience inadequate symptom control or expect faster symptom relief. A key advantage of the combination of mometasone furoate (nGCS) and olopatadine hydrochloride (an intranasal antihistamine) is their complementary and synergistic effects on the complex pathophysiology of AR.
Numerous clinical studies confirm the superior efficacy of the intranasal combination of olopatadine and mometasone (Olo-Mom) over monotherapy and placebo in the treatment of both seasonal (SAR) and perennial (PAR) allergic rhinitis. The combination of LH1+nGCS may also be associated with improved quality of life and ocular symptoms in children with ARS.
Key advantages and benefits of the Olo-Mom combination include: synergistic action, higher clinical efficacy, rapid onset, high patient satisfaction, improved adherence, and a favorable safety profile.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. Allergy Clin Immunol. 2017; 140(4): 950-58.
3. Fokkens WJ, Lund VJ, Hopkins C et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29): 1-464.
4. Gil-Mata S, Vieira RJ, Borowiack E et al. Intranasal treatments for allergic rhinitis in preschool- and school-aged children: network meta-analysis. J Allergy Clin Immunol Pract. 2025; S2213-2198(25)00636-1.
5. Lim L, Lipari M, Kale-Pradhan P. Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis. Ann Pharmacother. 2023; 57(5): 570-78.
6. Ridolo E, Barone A, Nicoletta F et al. Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/ mometasone furoate. Expert Rev Clin Immunol. 2023; 19(6): 575-84.
7. Ludger Klimek L, Klimek F, Bergmann C et al. Efficacy and safety of the combination nasal spray olopatadine hydrochloride- mometasone furoate in the treatment of allergic rhinitis. Allergo J Int. 2024; 33: 9-19.
8. Samoliński B, Wojas O, Lipiec A et al. Intranasal combo: fixed-dose combination of mometasone furoate and olopatadine hydrochloride in therapeutic strategies for rhinosinusitis. Otolaryngol Pol. 2023; 77(6): 43-50.
9. Patel P, Salapatek AM, Tantry SK. Effect of olopatadinemometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019; 122: 160.e1-166.e1.
10. Andrews CP, Mohar D, Salhi Y, Tantry SK. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2020; 124: 171.e2-178.e2.
11. Gross GN, Berman G, Amar NJ et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019; 122(6): 630-38.
12. Hampel FC, Pedinoff AJ, Jacobs RL et al. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019; 40: 261-72.
13. Fifer S, Toh L, Barkate H et al. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study. Patient Prefer Adherence. 2023; 17: 141-51.
14. Patterlini V, Guareschi F, D’Angelo D et al. Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays. Pharmaceutics 2024; 16: 989.